Fresenius SE & Co. KGaA Overview
Pro stress-test →Fresenius is a healthcare company providing products and services for chronically ill patients through two main operating segments: Fresenius Kabi and Fresenius Helios. The group also holds an investment stake in Fresenius Medical Care and operates Europe's leading private hospital network. The company is executing a strategic transformation (#FutureFresenius) focused on innovation in high-value therapy platforms.
Strategic Profile
Pro stress-test →Fresenius Kabi supplies critical therapies including intravenous drugs, nutrition products, infusion pumps, and cell therapy devices. The company raised full-year 2025 revenue guidance expecting up to 7% organic growth, with 6% organic revenue growth and 14% Core EPS growth achieved in recent quarters. Strategic initiatives include biosimilar expansion, cell therapy manufacturing partnerships, and local-for-local supply chain resilience.
Competitive Landscape
Pro stress-test →Key competitors include Fresenius Medical Care, Cardinal Health, Nipro, Steris, and ICU Medical. Fresenius competes across hospital operations (vs. regional operators), biopharma/generics (vs. major pharma and biosimilar companies), and medical devices. The company's diversified positioning and scale provide advantages in integrated healthcare solutions, though it faces margin pressures in generic drugs and competition in hospital management from specialized operators.
Industry Context
Fresenius SE & Co. KGaA operates in Healthcare - Pharmaceuticals, Medical Devices & Hospital Operations.
Key facts
Founded: 1912 · Headquarters: Bad Homburg, Germany · Employees: 177,356 · Revenue: $24.8B · Market cap: $30.6B